MariTide, a new drug from Amgen, helped some people with obesity lose up to 20% of their body weight. In a phase 2 trial, a new GLP-1 drug helped people lose up to 20% of their body weight over a year ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.

Apple (NASDAQ: AAPL) and Amgen (NASDAQ: AMGN), two well-established companies that are part of the iconic Dow Jones ...

US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...